Oncogenic protein tyrosine kinases

Abstract.Signals through Kit receptor tyrosine kinase are essential for development of erythrocytes, melanocytes, germ cells, mast cells and interstitial cells of Cajal (ICCs). Mice and rats with a double gene dose of loss-of-function mutations of Kit show depletion of these cells. Although human homozygotes with loss-of-function mutations of Kit have not been reported, gain-of-function mutations of Kit result in development of tumors from mast cells, germ cells and ICCs in humans. The ICC tumors are called gastrointestinal stromal tumors (GISTs), and GISTs are a good target for the Kit inhibitor imatinib mesylate. The interrelationship between the type of Kit gain-of-function mutations and the therapeutic effect of imatinib mesylate has been well characterized in GISTs. Kit is interesting from both a biological and clinical view-point.

[1]  C. Antonescu,et al.  Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[4]  Y. Matsuzawa,et al.  Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours , 2002, Gut.

[5]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[6]  M. Tatsuta,et al.  Spontaneous stomach ulcer in genetically mast-cell depleted W/Wv mice , 1980, Nature.

[7]  S. Galli,et al.  Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. , 1999, Experimental hematology.

[8]  T. Nishida,et al.  Gain‐of‐function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours , 2001, The Journal of pathology.

[9]  I. Lax,et al.  Kit Receptor Dimerization Is Driven by Bivalent Binding of Stem Cell Factor* , 1997, The Journal of Biological Chemistry.

[10]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[11]  Y. Matsuzawa,et al.  Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation , 1994 .

[12]  R. Ueda,et al.  Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. , 1991, Cancer research.

[13]  E. Morii,et al.  Characterization of Ws mutant allele of rats: a 12-base deletion in tyrosine kinase domain of c-kit gene. , 1991, Blood.

[14]  Yukihiko Kitamura,et al.  Decrease of mast cells in w/wv mice and their increase by bone marrow transplantation. , 1978 .

[15]  D. Longo,et al.  JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. , 1996, Blood.

[16]  A. Kuraishi,et al.  Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. , 2001, Gastroenterology.

[17]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[18]  H. Nakauchi,et al.  Production of interleukin 3 and gamma-interferon by an antigen-specific mouse suppressor T cell clone. , 1985, Journal of immunology.

[19]  D. Birnbaum,et al.  Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. , 1991, Oncogene.

[20]  A. Burns,et al.  Impaired development of interstitial cells and intestinal electrical rhythmicity in steel mutants. , 1995, The American journal of physiology.

[21]  S. Nishikawa,et al.  Requirement of c-kit for development of intestinal pacemaker system. , 1992, Development.

[22]  K. Nocka,et al.  Molecular bases of dominant negative and loss of function mutations at the murine c‐kit/white spotting locus: W37, Wv, W41 and W. , 1990, The EMBO journal.

[23]  Y. Kitamura,et al.  Age-dependent amelioration of hypoplastic anemia in Ws/Ws rats with a small deletion at the kinase domain of c-kit. , 1993, Blood.

[24]  P. Valent,et al.  Spectrum of Associated Clonal Hematologic Non-Mast Cell Lineage Disorders Occurring in Patients with Systemic Mastocytosis , 2002, International Archives of Allergy and Immunology.

[25]  David W. Andrews,et al.  Interstitial cells of Cajal generate a rhythmic pacemaker current , 1998, Nature Medicine.

[26]  O. Witte.  Steel locus defines new multipotent growth factor , 1990, Cell.

[27]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[28]  Y. Kitamura,et al.  Anemia and mast cell depletion in mutant rats that are homozygous at "white spotting (Ws)" locus. , 1991, Blood.

[29]  S. Hirota,et al.  Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. , 2002, Gastroenterology.

[30]  S. Nishikawa,et al.  Exon skipping by mutation of an authentic splice site of c-kit gene in W/W mouse. , 1991, Nucleic acids research.

[31]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[32]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[33]  K. Hartmann,et al.  Mastocytosis: recent advances in defining the disease , 2001, The British journal of dermatology.

[34]  S. Hirota,et al.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.

[35]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[36]  H. Kitayama,et al.  Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. , 1996, The American journal of pathology.

[37]  L. Sobin,et al.  Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. , 2000, The American journal of pathology.

[38]  D. Housman,et al.  The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene , 1988, Cell.

[39]  L. Ashman,et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.

[40]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[41]  Y. Sakuma,et al.  Alterations of the c‐kit gene in testicular germ cell tumors , 2003, Cancer science.

[42]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Y. Matsuzawa,et al.  Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. , 1996, Blood.

[44]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[45]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[46]  M. Tatsuta,et al.  Bile reflux: a possible cause of stomach ulcer in nontreated mutant mice of W/WV genotype. , 1982, Gastroenterology.

[47]  S. Hirota,et al.  Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. , 2000, The American journal of surgical pathology.

[48]  John Malysz,et al.  W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity , 1995, Nature.

[49]  Y. Matsuzawa,et al.  Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. , 1995, International archives of allergy and immunology.

[50]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[51]  C. Moskaluk,et al.  Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.

[52]  V. Chapman,et al.  The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus , 1988, Nature.

[53]  H. Kitayama,et al.  Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. , 1995, Blood.

[54]  C. Capella,et al.  Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa , 2001, Cancer.

[55]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[56]  Y. Matsuzawa,et al.  Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors , 2003, International journal of cancer.

[57]  Y. Kitamura,et al.  Coincidental development of forestomach papilloma and prepyloric ulcer in nontreated mutant mice of W/Wv and SI/SId genotypes. , 1980, Cancer research.

[58]  J. Soria,et al.  Imatinib in small cell lung cancer. , 2003, Lung cancer.

[59]  Laura H. Tang,et al.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.

[60]  O. Cummings,et al.  KIT mutations are common in testicular seminomas. , 2004, The American journal of pathology.

[61]  R. Spritz,et al.  Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[62]  M. Heinrich,et al.  KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. , 2002, The American journal of pathology.

[63]  S. Hirota,et al.  Familial gastrointestinal stromal tumours with germline mutation of the KIT gene , 1998, Nature Genetics.

[64]  S. Hirota,et al.  Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[65]  D. Linnekin,et al.  Early signaling pathways activated by c-Kit in hematopoietic cells. , 1999, The international journal of biochemistry & cell biology.

[66]  Y. Kitamura,et al.  Decreased production of mast cells in S1/S1d anemic mice. , 1979, Blood.

[67]  J. Schrader,et al.  Activation of the stress-activated protein kinases by multiple hematopoietic growth factors with the exception of interleukin-4. , 1997, Blood.

[68]  S. Hirota,et al.  Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. , 1995, Gastroenterology.

[69]  T. Jacks,et al.  Nf1 Regulates Hematopoietic Progenitor Cell Growth and Ras Signaling in Response to Multiple Cytokines , 1998, The Journal of experimental medicine.